menu search

Abcellera biologics: bebtelovimab supply deal provides a much needed shot in the arm

AbCellera announced on Thursday Feb 10th a supply deal with the US government and Lilly for Bebtelovimab, the AbCellera developed pan COVID variant ...

February 11, 2022, 8:45 am

Preprint suggests, vir-gsk's covid-19 antibody can evade omicron sub-variant

In January, amid the omicron surge, WHO's expert panel recommended GlaxoSmithKline Plc GSK / Vir Biotechnology Inc VIR and Eli Lilly And Co's L...

February 10, 2022, 3:09 pm

Preprint suggests, vir-gsk's covid-19 antibody can evade omicron sub-variant

In January, amid the omicron surge, WHO's expert panel recommended GlaxoSmithKline Plc GSK / Vir Biotechnology Inc VIR and Eli Lilly And Co's L...

February 10, 2022, 3:09 pm

Preprint suggests, vir-gsk's covid-19 antibody can evade omicron sub-variant

In January, amid the omicron surge, WHO's expert panel recommended GlaxoSmithKline Plc GSK / Vir Biotechnology Inc VIR and Eli Lilly And Co's L...

February 10, 2022, 3:09 pm

Gsk, vir say their covid antibody treatment can neutralize fast-spreading omicron relative

Lab studies suggest the antibody treatment, one of the few shown to be effective against omicron, will ...

February 10, 2022, 6:21 am

Gsk, vir say their covid antibody treatment can neutralize fast-spreading omicron relative

Lab studies suggest the antibody treatment, one of the few shown to be effective against omicron, will ...

February 10, 2022, 6:21 am

Gsk, vir say their covid antibody treatment can neutralize fast-spreading omicron relative

Lab studies suggest the antibody treatment, one of the few shown to be effective against omicron, will ...

February 10, 2022, 6:21 am

Why did igm biosciences shares advance today?

IGM Biosciences Inc IGMS has progressed two Phase 1 trials evaluating IGM-6268, an anti-SARS-CoV-2 IgM monoclonal antibody, to treat and prevent inf...

February 9, 2022, 3:34 pm

Why did igm biosciences shares advance today?

IGM Biosciences Inc IGMS has progressed two Phase 1 trials evaluating IGM-6268, an anti-SARS-CoV-2 IgM monoclonal antibody, to treat and prevent inf...

February 9, 2022, 3:34 pm

Why did igm biosciences shares advance today?

IGM Biosciences Inc IGMS has progressed two Phase 1 trials evaluating IGM-6268, an anti-SARS-CoV-2 IgM monoclonal antibody, to treat and prevent inf...

February 9, 2022, 3:34 pm

Gsk's covid-related sales close to $2 billion, profit boost to wane in 2022

GSK racked up 1.4 billion pounds ($1.9 billion) in COVID-related sales in 2021, largely for antibody dr...

February 9, 2022, 2:27 am

Gsk's covid-related sales close to $2 billion, profit boost to wane in 2022

GSK racked up 1.4 billion pounds ($1.9 billion) in COVID-related sales in 2021, largely for antibody dr...

February 9, 2022, 2:27 am

Gsk's covid-related sales close to $2 billion, profit boost to wane in 2022

GSK racked up 1.4 billion pounds ($1.9 billion) in COVID-related sales in 2021, largely for antibody dr...

February 9, 2022, 2:27 am

Immunome shares seesaw after covid-19 antibody cocktail works against live omicron virus

Immunome Inc IMNM shares rose before falling after reporting results from testing its experimental three-anti...

February 8, 2022, 3:00 pm

Immunome shares seesaw after covid-19 antibody cocktail works against live omicron virus

Immunome Inc IMNM shares rose before falling after reporting results from testing its experimental three-anti...

February 8, 2022, 3:00 pm

Immunome shares seesaw after covid-19 antibody cocktail works against live omicron virus

Immunome Inc IMNM shares rose before falling after reporting results from testing its experimental three-anti...

February 8, 2022, 3:00 pm

Top- and bottom-line beat gives regeneron stock a boost

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) is up 1.9% to trade at $632.42 at last check, after the drug maker posted a top- and bottom-line beat for...

February 4, 2022, 10:26 am

Top- and bottom-line beat gives regeneron stock a boost

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) is up 1.9% to trade at $632.42 at last check, after the drug maker posted a top- and bottom-line beat for...

February 4, 2022, 10:26 am

Top- and bottom-line beat gives regeneron stock a boost

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) is up 1.9% to trade at $632.42 at last check, after the drug maker posted a top- and bottom-line beat for...

February 4, 2022, 10:26 am

Regeneron shares up premarket after q4 revenue doubles and blows past estimates

Regeneron Pharmaceuticals Inc. shares REGN, -0.35% rose 1.8% in premarket trade Friday, after the company doubled its fourth-quarter revenue as sales ...

February 4, 2022, 6:41 am


Search within

Pages Search Results: